Data on Systemic Sclerosis Drug Candidate To Be Presented at Rare Disease Roundtable

Author: L. Ferreira
Date Published: October-2014
Source: Scleroderma News.com

The chief executive officer of clinical stage biopharmaceutical company Corbus Pharmaceuticals Holdings, Yuval Cohen, Ph.D., is presenting an update on the company’s research, as well as revision of previous clinical developments regarding Corbus’s lead product candidate, Resunab, at the Leerink Partners Rare Disease Roundtable. The product candidate is being studied by the drug developer as a possible treatment for rare, life-threatening inflammatory diseases, such as Systemic Sclerosis and Cystic Fibrosis.